Tracon Pharmaceuticals Inc., of San Diego, started a two-cohort trial consisting of a phase II study evaluating the combination of TRC102 and Alimta (pemetrexed, Eli Lilly and Co.) in patients with mesothelioma and a phase Ib study evaluating the combination of TRC102, Alimta and cisplatin in patients with solid tumors.